Back to home
REGULATORYApril 13, 2026·4 min read
FDA Approves Guardant360 as Companion Diagnostic for BRAF-Mutant CRC
Guardant Health's liquid biopsy test wins CDx approval for encorafenib in BRAF V600E-mutant metastatic colorectal cancer, expanding the utility of blood-based genomic profiling across cancer types.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.